Our scientific research is devoted to the creation and development of improved therapies that target hormone receptors
Our research supports a pipeline of clinical and preclinical product candidates that target various hormone receptors and have the potential to treat a variety of diseases. We use our experience and understanding of established hormone pathways to develop potential new medicines for serious medical conditions. The small molecules that we are developing selectively bind to and modulate hormone receptors but may display unique and improved clinical activities – acting as agonist (turning on) or antagonist (turning off, or blocking a more active agonist from binding) – depending on the tissue type.
Cell receptors, including hormone receptors, are special proteins found within cells. Cells of different types have receptors that are unique to them based on their function in the body. In other words, not all cell types have the same types of receptors. The pelvic floor and urinary sphincter are androgen receptor (AR) rich and can be modulated by androgenic agents.
The rationale for evaluating enobosarm as a treatment for SUI is supported by preclinical in vivo data demonstrating increases in pelvic floor muscle mass following treatment with GTx’s SARM compounds, including enobosarm, and the proof-of-concept Phase 2 clinical trial of enobosarm 3 mg for the treatment of postmenopausal women with SUI.